8 completed, 4 active not recruiting, 1 recruiting, 1 withdrawn. 9 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Active not recruiting 3, Completed 2, Recruiting 1 |
Follow Recurrent Primary Central Nervous System Neoplasm: new trials by email Literature Review of Recurrent Primary Central Nervous System Neoplasm trials Research Report on Recurrent Primary Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-06 |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Irinotecan, Pevonedistat, Temozolomide - Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2018-01-11 | 2024-10-22 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 33 | 2017-08-15 | 2025-01-14 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2017-02-27 | 2023-12-20 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Entinostat, Laboratory Biomarker Analysis, Pharmacological Study - Brain Stem Neoplasm, Pineal Region Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2017-01-06 | 2023-10-17 |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide - Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-07-14 | 2022-04-25 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
Central Nervous System Neoplasms (14) · Glioma (7) · Medulloblastoma (7) · Ependymoma (6) · Neuroblastoma (6) · Hepatoblastoma (5) · Histiocytosis, Langerhans-Cell (5) · Lymphoma, Non-Hodgkin (5) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Rhabdoid Tumor (5) · Wilms Tumor (5) · Osteosarcoma (4) · Rhabdomyosarcoma (4) · Sarcoma (4) · Lymphoma (3)
Neoplasms (14) · Neoplasms by Site (14) · Nervous System Diseases (14) · Nervous System Neoplasms (14) · Neoplasms by Histologic Type (12) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Nerve Tissue (11) · Neuroectodermal Tumors (11) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Neuroepithelial (10) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8)
Specimen Handling (6) · Magnetic Resonance Spectroscopy (5) · Phantoms, Imaging (5) · X-Rays (5) · Biopsy (3) · Nuclear Medicine Department, Hospital (3) · Irinotecan (2) · LY3023414 (2) · Temozolomide (2) · ensartinib (2) · erdafitinib (2) · tazemetostat (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · CTLA-4 Antigen (1) · Ipilimumab (1)
National Cancer Institute (NCI) (10) · Children's Oncology Group (3) · Nationwide Children's Hospital (1)
United States (14) · Canada (5) · Puerto Rico (5) · Australia (2)
Alice Lee (1) · Andrew Bukowinski (1) · Cynthia J Wetmore (1) · Daniel A Morgenstern (1) · Donald W Parsons (1) · Jason R Fangusaro (1) · Jennifer H Foster (1) · Margot Lazow, MD (1) · Meredith K Chuk (1) · Meredith S Irwin (1) · Ralph Salloum (1) · Stuart L Cramer (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 33591402, PMID 33881209, PMID 34486544, PMID 35353553, PMID 39487711, PMID 41166674, PMID 42686334
U10CA180886 (5), UM1CA097452 (5), UM1CA081457 (3), P30CA015704 (1), UM1CA154967 (1)